Direct conversion of astrocytes to dopamine neurons in vivo offers fresh optimism for the development of improved Parkinson's disease therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rivetti di Val Cervo, P. et al. Nat. Biotechnol. 35, 444–452 (2017).
Lindvall, O. et al. Science 247, 574–577 (1990).
Grealish, S. et al. Cell Stem Cell 15, 653–665 (2014).
Doi, D. et al. Stem Cell Rep. 2, 337–350 (2014).
La Manno, G. et al. Cell 167, 566–580.e19 (2016).
Caiazzo, M. et al. Nature 476, 224–227 (2011).
Liu, X. et al. Cell Res. 22, 321–332 (2012).
Masserdotti, G., Gascón, S. & Götz, M. Development 143, 2494–2510 (2016).
Cederfjäll, E. et al. Sci. Rep. 3, 2157 (2013).
Richardson, R.M. et al. Mol. Ther. 19, 1048–1057 (2011).
Marks, W.J. Jr., Baumann, T.L. & Bartus, R.T. Hum. Gene Ther. 27, 522–527 (2016).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dunnett, S., Rosser, A. Reprogramming the diseased brain. Nat Biotechnol 35, 426–428 (2017). https://doi.org/10.1038/nbt.3869
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3869